rigvir
Commercial- Indications
- Melanoma, Kidney cancer, Uterine cancer, Lung cancer, Colorectal cancer
Company intelligence / Profile preview
International Virotherapy Center coordinates access to virotherapy using the ECHO‑7 Rigvir oncolytic virus. Retrospective studies report prolonged survival and improved quality of life for patients with late-stage melanoma, small cell lung cancer, and histiocytic sarcoma treated with this therapy. In Latvia, approximately 75% of melanoma patients are treated with Rigvir. The product has been included in national guidelines there but remains unapproved or available only under special access programs elsewhere.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on International Virotherapy Center.